Skip to main content

Ovasave

Category: AI in Healthcare

Digital-first platform for women’s fertility testing, egg freezing, hormone management, and menopause care. Ovasave was founded in 2022. The company is led by Torkia Mahloul. Based in Abu Dhabi, UAE. Team size: 2-10. Total funding raised: USD 1.2 million. Latest round: Pre-Seed. Key investors include PlusVC, Annex Investments, 25 Madison, Strategic angel investors and prominent family offices from UAE and Saudi Arabia.

Founded
2022
Headquarters
Abu Dhabi, UAE
Team size
2-10
Total funding
USD 1.2 million

Value proposition

Empowers women to make proactive, informed reproductive health decisions by simplifying access to fertility testing, hormone monitoring, and egg freezing with teleconsultations and personalized care.

Products and solutions

At-home hormone and fertility testing (finger prick sample), Virtual consultations with fertility specialists, Egg freezing coordination and guidance, Personalized supplement protocols, Menopause and perimenopause care, Corporate reproductive health benefits programs, Mobile app with menstrual cycle tracking, symptom monitoring, AI-powered cycle insights, and supplement management

Unique value

First and most trusted FemTech platform in Middle East focused holistically on fertility, hormonal health, and menopause with a seamless digital-first user experience; integrates at-home testing with virtual care and fertility preservation services tailored for the MENA region.

Target customer

Women in the MENA region seeking fertility and hormonal health solutions; corporate partners for employee reproductive health benefits.

Industries served

FemTech, Healthcare, Corporate Wellness

Technology advantage

Combination of at-home testing, virtual fertility expertise, personalized supplements, and access to top regional fertility clinics with a culturally tuned approach; developing AI-driven protocols via upcoming app features.

How they differentiate

Ovasave’s edge lies in a MENA-focused, culturally sensitive platform combining fertility testing, egg freezing, hormone and menopause care with an integrated digital-first experience and regional clinic access.

Main competitors

Alife Health, Maven Clinic, Tia

Key partnerships

Partnerships with top fertility clinics in the MENA region, Corporate partnerships for employee reproductive health benefit schemes, Investment and strategic support from regional investors such as PlusVC, Annex Investments, 25 Madison, and leading family offices indicate network collaboration

Notable customers

Several corporate clients in GCC adopting reproductive health benefits via Ovasave platform (specific names not publicly disclosed).

Major milestones

First FemTech startup in MENA to raise US$1.2 million in a pre-seed round focused on fertility and hormonal health, Launched Ovasave mobile app with AI-powered cycle tracking, symptom monitoring, and teleconsultation features (iOS & Android), Named to Fast Company's World's Most Innovative Companies list (2026), Growing presence as a trusted platform for women's fertility preservation and menopause care in the region

Growth metrics

Rapid corporate partnership growth with expanding employee reproductive health schemes; preparing for next app phase launch targeting wider user engagement.

Market positioning

Emerging FemTech pioneer in Gulf Cooperation Council (GCC) and broader MENA region seeking to disrupt traditional fertility and hormonal health care via tech innovation.

Geographic focus

Primary focus on the GCC countries (UAE, Saudi Arabia, etc.) with plans to expand regionally across MENA.

Patents and IP

N/A

About Torkia Mahloul

Over a decade of diverse experience in corporate banking, consumer products, and tech; worked with top financial institutions and multinationals and startups globally; specialized in launching new products and markets; personal experience with egg freezing informs mission.

Official website: